Array BioPharma, Inc. has achieved an $8.5 million milestone in its collaboration with Amgen for the worldwide development of the small-molecule glucokinase activator (GKA) program, including AMG 151. The milestone was achieved after reaching predefined patient enrollment in a Phase IIa trial.   The Phase IIa trial is a randomized, double-blind, placebo-controlled study of AMG 151 in combination with metformin in patients with type 2 diabetes. The primary endpoint is change in fasting plasma glu...